|

KEYTRUDA® (pembrolizumab) Clinical Trials

7 actively recruiting trials across 5 locations

Also known as: MK-3475

Pipeline

Phase 1: 3Phase 1/2: 4

Top Sponsors

  • Qurient Co., Ltd.1
  • Phanes Therapeutics1
  • Krystal Biotech, Inc.1
  • HC Biopharma Inc.1
  • Flare Therapeutics Inc.1

Indications

  • Cancer7
  • Advanced Cancer2
  • Open Label1
  • Oral Drug Administration1
  • Gastric or Gastroesophageal Junction Adenocarcinoma1

Other2 trials

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Phase 1

Phoenix, Arizona1 trial

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Mayo Clinic

Phase 1/2

Duarte, California1 trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Los Angeles, California1 trial

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

UCLA Health

Phase 1/2

San Francisco, California1 trial

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1

Cleveland, Ohio1 trial

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

UH Cleveland Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.